Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
PDF) Psychological Predictors of Negative Treatment Outcome with Erenumab in Chronic Migraine: Data From an Open Label Long-Term Prospective Study
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study | The Journal of Headache and Pain | Full Text
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment - The Lancet Neurology
Does erenumab suspension affect chronic migraine course? A real life experience
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
PDF) Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
IHC 2019 Late Breaking Abstracts, 2019
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine: Expert Opinion on Drug Safety: Vol 20, No 4
CONCLUSIONS BACKGROUND OBJECTIVE METHODS RESULTS REFERENCES ACKNOWLEDGEMENTS RESULTS (CONTINUED)
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
PDF) Migraine and COVID-19 lockdown
PDF) Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
Does erenumab suspension affect chronic migraine course? A real life experience
